|
|
|
Insider
Information: |
Emster Kurt Von |
Relationship: |
Director |
City: |
|
State: |
|
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
7 |
|
Direct
Shares |
302,614 |
|
Indirect Shares
|
18,297,697 |
|
|
Direct
Value |
$5,540,734 |
|
|
Indirect Value
|
$162,403,202 |
|
|
Total
Shares |
18,600,311 |
|
|
Total
Value |
$167,943,937 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
0
|
0
|
Stock
price went up :
|
0
|
0
|
Stock
price went down : |
0
|
0
|
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
Percentage
Gain/Loss : |
0.0%
|
0.0%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
![](../../../Gifs/iconPlus.jpg) |
Rigel Pharmaceuticals Inc |
RIGL |
10% Owner |
2003-06-26 |
173,611 |
2004-02-19 |
4,350,516 |
Premium* |
![](../../../Gifs/iconPlus.jpg) |
Somaxon Pharmaceuticals, Inc. |
SOMX |
Director |
2013-03-06 |
0 |
2013-03-06 |
0 |
Premium* |
![](../../../Gifs/iconPlus.jpg) |
Crispr Therapeutics Ag |
CRSP |
Director |
2018-06-05 |
90,000 |
2018-12-18 |
1,171,268 |
Premium* |
![](../../../Gifs/iconPlus.jpg) |
Cymabay Therapeutics, Inc. |
CBAY |
|
2024-03-22 |
0 |
2023-09-29 |
18,406 |
Premium* |
![](../../../Gifs/iconPlus.jpg) |
Vaxcyte, Inc. |
PCVX |
Director |
2020-06-16 |
0 |
2020-06-16 |
4,168,718 |
Premium* |
![](../../../Gifs/iconPlus.jpg) |
Vera Therapeutics, Inc. |
VERA |
Director |
2021-05-17 |
17,828 |
2021-05-18 |
2,960,231 |
Premium* |
![](../../../Gifs/iconPlus.jpg) |
Amplitude Healthcare Acquisition... |
AMHCU |
Director |
2023-04-13 |
21,175 |
2021-09-24 |
5,628,558 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
108 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 4 of 5
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
CRSP |
Crispr Therapeutics Ag |
Director |
|
2017-06-28 |
4 |
AS |
$17.04 |
$538,328 |
I/I |
(31,592) |
2,456,419 |
0 |
- |
|
CBAY |
Cymabay Therapeutics, Inc... |
Director |
|
2017-10-03 |
4 |
S |
$7.81 |
$554,041 |
I/I |
(70,940) |
1,280,000 |
0 |
- |
|
CRSP |
Crispr Therapeutics Ag |
Director |
|
2017-07-13 |
4 |
AS |
$16.87 |
$567,321 |
I/I |
(33,629) |
2,392,806 |
0 |
- |
|
CRSP |
Crispr Therapeutics Ag |
Director |
|
2017-06-27 |
4 |
AS |
$17.43 |
$582,755 |
I/I |
(33,434) |
2,488,011 |
0 |
- |
|
CRSP |
Crispr Therapeutics Ag |
Director |
|
2017-08-14 |
4 |
AS |
$19.64 |
$588,866 |
I/I |
(29,983) |
2,143,017 |
0 |
- |
|
CRSP |
Crispr Therapeutics Ag |
Director |
|
2017-07-14 |
4 |
AS |
$16.82 |
$609,389 |
I/I |
(36,230) |
2,356,576 |
0 |
- |
|
CRSP |
Crispr Therapeutics Ag |
Director |
|
2017-07-27 |
4 |
AS |
$17.63 |
$721,074 |
I/I |
(40,912) |
2,282,734 |
0 |
- |
|
CBAY |
Cymabay Therapeutics, Inc... |
Director |
|
2018-12-17 |
4 |
S |
$8.17 |
$726,223 |
I/I |
(88,889) |
184,528 |
0 |
- |
|
CBAY |
Cymabay Therapeutics, Inc... |
Director |
|
2017-09-28 |
4 |
S |
$8.15 |
$736,670 |
I/I |
(90,389) |
1,509,611 |
0 |
- |
|
CBAY |
Cymabay Therapeutics, Inc... |
Director |
|
2018-02-13 |
4 |
AS |
$13.51 |
$744,104 |
I/I |
(55,078) |
518,461 |
0 |
- |
|
CRSP |
Crispr Therapeutics Ag |
Director |
|
2016-10-24 |
4 |
B |
$14.00 |
$784,000 |
I/I |
56,000 |
2,601,814 |
2.1 |
- |
|
CRSP |
Crispr Therapeutics Ag |
Director |
|
2017-06-26 |
4 |
AS |
$16.83 |
$807,857 |
I/I |
(48,001) |
2,521,445 |
0 |
- |
|
CRSP |
Crispr Therapeutics Ag |
Director |
|
2017-08-03 |
4 |
AS |
$17.77 |
$842,458 |
I/I |
(47,409) |
2,229,413 |
0 |
- |
|
CBAY |
Cymabay Therapeutics, Inc... |
Director |
|
2017-09-29 |
4 |
S |
$8.04 |
$970,709 |
I/I |
(120,735) |
1,388,876 |
0 |
- |
|
CBAY |
Cymabay Therapeutics, Inc... |
Director |
|
2018-02-15 |
4 |
AS |
$14.49 |
$995,637 |
I/I |
(68,712) |
286,770 |
0 |
- |
|
CBAY |
Cymabay Therapeutics, Inc... |
Director |
|
2017-07-19 |
4 |
B |
$6.50 |
$999,999 |
I/I |
153,846 |
1,753,846 |
2.1 |
- |
|
CRSP |
Crispr Therapeutics Ag |
Director |
|
2018-01-02 |
4 |
AS |
$26.76 |
$1,010,123 |
I/I |
(37,754) |
1,913,605 |
0 |
- |
|
CBAY |
Cymabay Therapeutics, Inc... |
Director |
|
2018-01-30 |
4 |
AS |
$12.22 |
$1,042,843 |
I/I |
(85,339) |
581,685 |
0 |
- |
|
CBAY |
Cymabay Therapeutics, Inc... |
Director |
|
2018-02-01 |
4 |
AS |
$12.15 |
$1,070,391 |
I/I |
(88,098) |
481,287 |
0 |
- |
|
CBAY |
Cymabay Therapeutics, Inc... |
Director |
|
2018-01-19 |
4 |
AS |
$10.25 |
$1,338,486 |
I/I |
(130,584) |
844,715 |
0 |
- |
|
CBAY |
Cymabay Therapeutics, Inc... |
Director |
|
2018-01-22 |
4 |
AS |
$10.40 |
$1,437,831 |
I/I |
(138,253) |
706,462 |
0 |
- |
|
CRSP |
Crispr Therapeutics Ag |
Director |
|
2018-01-05 |
4 |
B |
$22.75 |
$1,499,999 |
I/I |
65,934 |
1,887,202 |
2.1 |
- |
|
CBAY |
Cymabay Therapeutics, Inc... |
Director |
|
2017-12-22 |
4 |
AS |
$9.41 |
$1,629,304 |
I/I |
(173,192) |
993,231 |
0 |
- |
|
CRSP |
Crispr Therapeutics Ag |
Director |
|
2017-08-28 |
4 |
AS |
$19.79 |
$1,741,738 |
I/I |
(88,011) |
1,951,359 |
0 |
- |
|
CRSP |
Crispr Therapeutics Ag |
Director |
|
2018-12-18 |
4/A |
S |
$29.70 |
$1,869,168 |
I/I |
(62,925) |
1,171,268 |
0 |
- |
|
108 Records found
|
|
Page 4 of 5 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|